DJIA 18,203.37 -85.26 -0.47%
NASDAQ 4,979.90 -28.20 -0.56%
S&P 500 2,107.78 -9.61 -0.45%
market minute promo

Synageva BioPharma (NASDAQ: GEVA)

101.72 1.12 (1.11%)

REAL-TIME: Last trade at

Extended Hours: $101.72 $0.00 (0.00%)
Quote as of (NASDAQ)



company name or ticker

Recent Quotes

GEVA $101.72 1.11%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $97.92
Previous Close $100.60
Daily Range $95.52 - $102.17
52-Week Range $60.19 - $122.88
Market Cap $3.8B
P/E Ratio -17.08
Dividend (Yield) $0.00 (0.0%)
Volume 292,089
Average Daily Volume 320,312
Current FY EPS -$6.45

Sector

Healthcare

Industry

Drug Makers

Synageva BioPharma (GEVA) Description

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of a new class of antiviral drug treatments called fusion inhibitors. Website: http://www.synageva.com/

News & Commentary

An $8 Billion Hedge Fund Bought This Extremely Risky Stock: Should You?

The healthcare gurus known as the Baker Brothers have amassed a huge position in the orphan drugmaker Synageva BioPharma Corp. Should investors follow in their footsteps?

Wedbush Securities Sees Preparations Continuing For Expected Approval And Strong Launch Of Kanuma Fo

Wedbush Securities Sees Preparations Continuing For Expected Approval And Strong Launch Of Kanuma For Synageva Biopharma

Synageva BioPharma's (GEVA) CEO Sanj Patel on Q4 2014 Results - Earnings Call Transcript

Health Care Sector Update for 02/23/2015: RIGL, CLDX, GEVA

Health Care Sector Update for 02/18/2015: GEVA, ENZY, BCRX

Use Options For a Chance To Buy GEVA at a 38% Discount

Synageva Starts Dosing in Phase I/II Study for Sanfilippo B - Analyst Blog

Synageva BioPharma Announces Dosing Of Patients Commenced With SBC-103 In Phase 1/2 Study For Mucopo

Synageva BioPharma Announces Dosing Of Patients Commenced With SBC-103 In Phase 1/2 Study For Mucopolysaccharidosis IIIB And FDA Fast Track Designation Granted

Insiders Bullish On Certain Holdings Of TWOK

Why You Shouldn't Bet Against Synageva BioPharma (GEVA) Stock - Tale of the Tape

See More GEVA News...

GEVA's Top Competitors

GEVA $101.72 (1.11%)
Current stock: GEVA
AMGN $158.56 (-0.67%)
Current stock: AMGN
GILD $102.79 (-1.00%)
Current stock: GILD
BIIB $412.79 (-0.72%)
Current stock: BIIB